CSIMarket Company Name, Ticker, Industry, else..
 
Ambarella Inc   (AMBA)
Other Ticker:  
 
    Sector • Technology    Industry • Semiconductors
   Industry • Semiconductors
   Sector • Technology
 


The Semiconductors company disclosed a simple Revenues growth, in the most recent fiscal period

company delivered third quarter of 2023 operating loss of $-20.13 millions

Published 2023-03-26T05:11:29+00:00
Goran Soko / CSIMarket.com Contributer
Inside_a_computer_By_nrkbeta_(originally_posted_to_Flickr_as_Maskinvare)__[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_CommonFor the most recent fiscal period company realized net deficit per share of $-0.51 compared to $-0.20 a year prior, while Revenues advanced by 4.751 % to $83.10 millions from the comparable quarter a year prior.

In the preceding quarter AMBA realized Revenue of $90.31 millions and bottom line of $-0.29 per share.


For the third quarter of 2023 earnings season Ambarella Inc realized net loss of $-19.809 million, bigger than $-7.156 million a year ago.


Ambarella Inc is expected to report next financial results on March 31, 2023.


Ambarella Inc stock quotes, charts, profile

Ambarella Inc Income Statement, Balance sheets, Cash Flow Statement
    Recently Reported Results
Grocery_Section_By_Maryland_Pride_Own_work__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common Dillard S Inc

Revenues and Profits Increased at the Dillard S Inc amid the fiscal three months closing Jan 28 2023

DDS reported moderate Revenue advance of 0.422 % to $2.16 billions in the November to January 28 2023 period, income grew slight by 1.81 % to $16.89 year on year.

Dillard S Inc Customers

Dillard S Inc advance Rates, Profitability, PE
Supercenter_Theonlysilentbob_at_en.wikipedia__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Common Retail Sales

U.S. retail sales on the rise again in January 2023, after recent declines

Good news came from the Retail sales report, as it shows improvement after months of deterioration, as willingness of consumers to spend increase.

Advance monthly sales full report

Advance monthly sales growth
interior_Joe_Mabel_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons Cullman Bancorp Inc

Considering the October to December 31 2022 interval CULL bottom-line turned positive at $0.12 per share, relative to the earnings of $-0.03 per share a year ago reporting period, In the prior reporting period CULL realized $0.13 per share.

Cullman Bancorp Inc Competitors, Market Share

Cullman Bancorp Inc elevation Rates, Profitability, PE
financial-building-waterloo-ontario_By_Giligone_(Own_work_using_Sony_Alpha_200_DSLR)__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg Conifer Holdings Inc

A modest 3.692%, rise in Revenues at Conifer Holdings Inc over the most recent fiscal period

For the fourth quarter of 2022 earnings season Conifer Holdings Inc had turn a round to earnings by displaying earnings per share of $0.15 per share compare to $-0.08 a year prior and earnings per share turned positive from $-0.14 per share from the preceding quarter.

Revenue increased modest by 3.692 % to $28.50 millions from $27.49 millions in the same quarter a year prior and sequentially Revenues advanced by 8.232 % from $26.34 millions.

Conifer Holdings Inc Suppliers

Conifer Holdings Inc elevation Rates, Profitability, PE
Dryvax_pd Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals Inc published operating deficit of $-14.562 millions, in the October to December 31 2022

The investors haven't anticipated some changes at the business during the the earnings season of the October to December 31 2022 time at the Reneo Pharmaceuticals Inc . But, shareholders consider the Major Pharmaceutical Preparations company's operating deficit which was at $-14.562 millions, during the same period.

Reneo Pharmaceuticals Inc Customers

Reneo Pharmaceuticals Inc Suppliers
Montage_By_Michael_Schmahl_(Own_work)__[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons Construction Spending

Construction spending rebounded in January 2023

Outlays for U.S. construction projects increased again after dipping in the last month, led by growth in construction outlays for health care, residential and nonresidential construction.
Loxley_Farm_Market_Produce_By_Infrogmation_of_New_Orleans_[CC-BY-SA-3.0_(http_creativecommons.org_licensesby-sa3.0)]_via_Wikimedia_Commons Consumer Price Index

Inflation on the rise again in January 2023

U.S. Consumer prices rose again after dipping in the last month, led by increase in gasoline prices.
unemployed_lines_pd Employment Report

Economy gains 223,000 jobs, unemployment rate 3.5 %

The nonfarm payrolls grew 223,000 in December, as faster hiring puts more money in the hands of consumers, what usually leads to an increase in spending,

Dryvax_pd Impel Pharmaceuticals Inc

In the most recent fiscal period company decreased a loss per share at $-0.98 per share, opposite of $-1.06 per share a year ago reporting period, In the previous reporting period Impel Pharmaceuticals Inc realized $-1.31 per share.

Impel Pharmaceuticals Inc Competitors, Market Share

Impel Pharmaceuticals Inc Revenue improvement Rates
Dryvax_pd Cytomx Therapeutics Inc

Considering the fourth quarter of 2022 earnings season the Major Pharmaceutical Preparations company lost money at $-0.42 per share, relative to the results of $-0.91 per share a year prior reporting period, In the prior reporting period the Cytomx Therapeutics Inc realized $-0.35 per share.

Cytomx Therapeutics Inc Customers

Cytomx Therapeutics Inc Income Statement, Balance sheets, Cash Flow Statement
Dryvax_pd Acer Therapeutics Inc

For the fiscal interval closing December 31 2022 ACER increased a deficit per share of $-0.54 per share compare to $-0.30 a year ago and advanced deficit from $-0.31 per share from the preceding reporting season.

Revenues remained unaltered to $0.00 millions from $0.36 millions in the similar reporting season a year ago and sequentially Revenue Tumbled from $0.00 millions.

Acer Therapeutics Inc stock quotes, charts, profile

Acer Therapeutics Inc Revenue elevation Rates
Pennsylvania Real Estate Investment Trust

Deficit higher than a year ago at the Pennsylvania Real Estate Investment Trust during the financial fourth quarter of 2022

For the financial fourth quarter of 2022 PRET Diminishing Returns have swelled of $-7.81 per share compare to $-0.43 a year ago and EPS improved from $-14.52 per share from the previous financial reporting period.

Revenues decreased by -5.307 % to $80.65 millions from $85.17 millions in the same financial reporting period a year ago and sequentially Revenues advanced by 10.767 % from $72.81 millions.

Pennsylvania Real Estate Investment Trust Competitors, Market Share

Pennsylvania Real Estate Investment Trust Revenue improvement Rates
Dryvax_pd Terns Pharmaceuticals Inc

For the fourth quarter of 2022 Terns Pharmaceuticals Inc decreased a loss per share of $-0.23 per share compare to $-0.56 a year prior and EPS improved from $-0.44 per share from the prior quarter.

Revenues remained unaffected to $0.00 millions from $1.00 millions in the corresponding quarter a year prior and sequentially Revenues advanced from $0.00 millions.

Terns Pharmaceuticals Inc Suppliers

Terns Pharmaceuticals Inc Suppliers
Terex_haul_truck_By_Lindsay__[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Common Gold Royalty Corp

For the fiscal span ending December 31 2022 company lost money of $-0.14 per share compare to $-0.14 a year before and from $0.00 per share from the preceding quarter.

Revenues remained unchanged by 0 % to $3.94 millions from $3.94 millions in the same quarter a year before and sequentially Revenues advanced from $0.00 millions.

Gold Royalty Corp Customers

Gold Royalty Corp Suppliers


Other AMBA's Earnings Reports

Ambarella Inc reported third quarter 2022 earnings

Ambarella Inc reported second quarter 2022 earnings

Ambarella Inc reported first quarter 2022 earnings
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

 Stocks


Event Calendar

AXTI's Profile

Stock Price

AXTI's Financials

Business Description

Fundamentals

Charts & Quotes

AXTI's News

Suppliers

AXTI's Competitors

Customers & Markets

Economic Indicators

AXTI's Growth

Company Segments

 Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness
Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

 Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

 News


At a Glance

Stocks

Economy

Industries

Other
Help


Sitemap

Advertise

About us

 Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071